Hybrid adenovirus-AAV virus and methods of use thereof

Claim 2

A recombinant, replication-defective, hybrid virus comprising: (a) adenovirus sequences comprising the adenovirus 5' and 3' cis-elements necessary for replication and virion encapsidation; (b) adeno-associated virus (AAV) sequences comprising the 5' and 3' inverted terminal repeats (ITRs) of an AAV, said AAV sequences flanked by the adenovirus sequences of (a); and (c) a selected transgene operatively linked to sequences which regulate its expression in a target cell, said gene and regulatory sequences flanked by the AAV sequences of (b), wherein the hybrid virus is provided with sufficient adenovirus sequences to permit infection of a target cell and stable integration of the transgene into the target cell in the presence of a functional portion of an AAV rep gene.

Claim 3

(Amended) The hybrid virus according to claim 1 wherein said adenovirus sequences comprise a functional deletion in the E1 gene.

Claim 4

The hybrid virus according to claim 1 wherein said adenovirus sequences comprise functional deletions in one or more of the adenovirus genes selected from the group consisting of the E2a gene, the E4 gene, the late genes L1 through L5, and the intermediate genes IX and IV a .

Claim 5

The hybrid virus according to claim 1 wherein said selected trans gene is a reporter gene.

Claim 6

The hybrid virus according to claim 1 wherein said selected trans gene is a therapeutic gene.

Claim 7

The hybrid virus according to claim 1 further comprising an adeno-associated virus rep gene.

Claim 8

The hybrid virus according to claim 1 in which the sequences which regulate expression of a transgene comprise sequences selected from the group consisting of the cytomegalovirus immediate-early enhancer/promoter; the Rous sarcoma virus LTR promoter/enhancer and the chicken β-actin promoter.

Claim 9

A method for producing high levels of a recombinant adeno-associated virus in a cultured cell comprising the step of culturing a cell containing the virus of claim 1 and an optional helper virus in the presence of a plasmid containing an AAV rep gene under control of sequences which regulate expression of said rep gene so as to produce recombinant adeno-associated virus.

Claim 10

The hybrid virus according to claim 2 wherein said adenovirus sequences comprise a functional deletion in the E3 gene.

Claim 11

The hybrid virus according to claim 4 wherein said reporter gene is selected from the group consisting of the genes encoding β-galactosidase, alkaline phosphatase and green fluorescent protein.

Claim 12

The hybrid virus according to claim 5 wherein said therapeutic gene is selected from the group consisting of a normal CFTR gene and a normal LDL gene.

Claim 13

A recombinant trans-infection particle comprising: (a) a recombinant, replication-defective, hybrid virus comprising: (i) adenovirus sequences comprising the adenovirus 5' and 3' cis-elements necessary for replication and virion encapsidation; (ii) adeno-associated virus (AAV) sequences comprising the 5' and 3' inverted terminal repeats (ITRs) of an adeno-associated virus, said AAV sequences flanked by the adenovirus sequences of (i); and (iii) a selected trans ene operatively linked to sequences which regulate its expression in a target cell, said transgene and regulatory sequences flanked by the AAV sequences of (ii), wherein the hybrid virus is provided with sufficient adenovirus sequences to permit infection of a target cell and stable integration of the transgene into the target cell in the presence of a functional portion of an AAV rep gene; (b) a polycation sequence conjugated to said hybrid virus; and (c) a plasmid comprising a functional portion of an AAV rep gene operatively linked to sequences which regulate its expression, said plasmid bound to said polycation sequence.

Claim 14

A recombinant trans-infection particle comprising: (a) a recombinant, replication-defective, hybrid virus comprising: (i) adenovirus sequences comprising the adenovirus 5' and 3' cis-elements necessary for replication and virion encapsidation; (ii) adeno-associated virus (AAV) sequences comprising the 5' and 3' inverted terminal repeats (ITRs) of an adeno-associated virus, said AAV sequences flanked by the adenovirus sequences of (i); and (iii) a selected trans ene operatively linked to sequences which regulate its expression in a target cell, said transgene and regulatory sequences flanked by the AAV sequences of (ii), wherein the hybrid virus is provided with sufficient adenovirus sequences to permit infection of a target cell and stable integration of the transgene into the target cell in the presence of a functional portion of an AAV rep gene; (b) a polycation sequence conjugated to said hybrid virus; and (c) a plasmid comprising a functional portion of an AAV rep gene operatively linked to sequences which regulate its expression, said plasmid bound to said polycation sequence.

Claim 15

The trans-infection particle according to claim 12 wherein said adenovirus sequences comprise a functional deletion in the E1 gene.

Claim 16

The trans-infection particle according to claim 12 wherein said adenovirus sequences comprise functional deletions in one or more of the adenovirus genes selected from the group consisting of the E2a gene, the E4 gene, the late genes L1 through L5, and the intermediate genes IX and IV a .

Claim 17

The trans-infection particle according to claim 12 wherein said selected trans gene is a reporter gene.

Claim 18

The trans-infection particle according to claim 15 wherein said reporter gene is selected from the group consisting of the genes encoding β-galactosidase, alkaline phosphatase and green fluorescent protein.

Claim 19

The trans-infection particle according to claim 12 wherein said selected trans gene is a therapeutic gene.

Claim 20

The trans-infection particle according to claim 17 wherein said therapeutic gene is selected from the group consisting of a normal CFTR gene and a normal LDL gene.

Claim 21

A method for producing high levels of a recombinant adeno-associated virus in a cultured cell comprising the step of culturing a cell containing the particle of claim 12 so as to produce recombinant adeno-associated virus.

Claim 22

The trans-infection particle according to claim 12 in which the sequences which regulate expression of a transgene comprise sequences selected from the group consisting of the cytomegalovirus immediate-early enhancer/promoter; the Rous sarcoma virus LTR promoter/enhancer and the chicken β-actin promoter.

Claim 23

The method according to claim 8 further comprising the step of isolating from said culture a recombinant AAV.

Claim 24

The method according to claim 19 further comprising the step of isolating from said culture a recombinant AAV.

Claim 25

A mammalian cell containing the hybrid virus of claim 1 or the trans-infection particle of claim 12.

Claim 26

The trans-infection particle according to claim 13 wherein said adenovirus sequences comprise a functional deletion in the E3 gene.

Claim 27

A composition which delivers and stably integrates a selected transgene into the chromosome of a target cell, said composition comprising (a) a recombinant, replication-defective, hybrid virus comprising: (i) adenovirus sequences comprising the adenovirus 5' and 3' cis-elements necessary for replication and virion encapsidation; (ii) adeno-associated virus (AAV) sequences comprising the 5' and 3' inverted terminal repeats (ITRs) of an adeno-associated virus, said AAV sequences flanked by the adenovirus sequences of (i); and (iii) a selected ransgene operatively linked to sequences which regulate its expression in a target cell, said transgene and regulatory sequences flanked by the AAV sequences of (ii), and (iv) a functional portion of an AAV rep gene under the control of sequences which regulate expression of said functional portion of the rep gene in the target cell; wherein the hybrid virus is provided with sufficient adenovirus sequences to permit infection of a target cell and stable integration of the transgene into the target cell in the presence of a functional portion of an AAV rep gene; and (b) a pharmaceutically acceptable carrier.

Claim 28

A composition which delivers and stably integrates a selected transgene into the chromosome of a target cell, said composition comprising (a) a recombinant, replication-defective, hybrid virus comprising: (i) adenovirus sequences comprising the adenovirus 5' and 3' cis-elements necessary for replication and virion encapsidation; (ii) adeno-associated virus (AAV) sequences comprising the 5' and 3' inverted terminal repeats (ITRs) of an adeno-associated virus, said AAV sequences flanked by the adenovirus sequences of (i); and (iii) a selected ransgene operatively linked to sequences which regulate its expression in a target cell, said transgene and regulatory sequences flanked by the AAV sequences of (ii), and (iv) a functional portion of an AAV rep gene under the control of sequences which regulate expression of said functional portion of the rep gene in the target cell; wherein the hybrid virus is provided with sufficient adenovirus sequences to permit infection of a target cell and stable integration of the transgene into the target cell in the presence of a functional portion of an AAV rep gene; and (b) a pharmaceutically acceptable carrier.

Claim 29

The composition according to claim 25 wherein said functional portion of the rep gene encodes the rep 78 and 52 proteins.

Claim 30

A composition which delivers stably integrates a selected transgene into the chromosome of a target cell comprising an effective amount of a recombinant trans-infection particle in a pharmaceutically acceptable carrier, said particle comprising: (a) a recombinant, replication-defective, hybrid virus comprising: (i) adenovirus sequences comprising the adenovirus 5' and 3' cis-elements necessary for replication and virion encapsidation; (ii) adeno-associated virus (AAV) sequences comprising the 5' and 3' inverted terminal repeats (ITRs) of an adeno-associated virus, said AAV sequences flanked by the adenovirus sequences of (i); and (iii) a selected ransgene operatively linked to sequences which regulate its expression in a target cell, said transgene and regulatory sequences flanked by the AAV sequences of (ii); wherein the hybrid virus is provided with sufficient adenovirus sequences to permit infection of a target cell and stable integration of the transgene into the target cell in the presence of a functional portion of an AAV rep gene; (b) a polycation sequence conjugated to said hybrid virus; (c) a plasmid comprising a functional portion of an AAV rep gene operatively linked to sequences which regulate its expression, said plasmid bound to said polycation sequence.

Claim 31

A composition which delivers stably integrates a selected transgene into the chromosome of a target cell comprising an effective amount of a recombinant trans-infection particle in a pharmaceutically acceptable carrier, said particle comprising: (a) a recombinant, replication-defective, hybrid virus comprising: (i) adenovirus sequences comprising the adenovirus 5' and 3' cis-elements necessary for replication and virion encapsidation; (ii) adeno-associated virus (AAV) sequences comprising the 5' and 3' inverted terminal repeats (ITRs) of an adeno-associated virus, said AAV sequences flanked by the adenovirus sequences of (i); and (iii) a selected ransgene operatively linked to sequences which regulate its expression in a target cell, said transgene and regulatory sequences flanked by the AAV sequences of (ii); wherein the hybrid virus is provided with sufficient adenovirus sequences to permit infection of a target cell and stable integration of the transgene into the target cell in the presence of a functional portion of an AAV rep gene; (b) a polycation sequence conjugated to said hybrid virus; (c) a plasmid comprising a functional portion of an AAV rep gene operatively linked to sequences which regulate its expression, said plasmid bound to said polycation sequence.

Claim 34

The method according to claim 28 further comprising the step of isolating from said culture a recombinant AAV.

Claim 35

A mammalian host cell comprising a recombinant, replication-defective, hybrid vector comprising: (i) adenovirus sequences comprising the adenovirus 5' and 3' cis-elements necessary for replication and virion encapsidation; (ii) adeno-associated virus (AAV) sequences comprising the 5' and 3' inverted terminal repeats (ITRs) of an adeno-associated virus, said AAV sequences flanked by the adenovirus sequences of (i); and (iii) a selected transgene operatively linked to regulatory sequences which direct its expression in a target cell, said transgene and regulatory sequences flanked by the AAV sequences of (ii).

Claim 36

A mammalian host cell comprising a recombinant, replication-defective, hybrid vector comprising: (i) adenovirus sequences comprising the adenovirus 5' and 3' cis-elements necessary for replication and virion encapsidation; (ii) adeno-associated virus (AAV) sequences comprising the 5' and 3' inverted terminal repeats (ITRs) of an adeno-associated virus, said AAV sequences flanked by the adenovirus sequences of (i); and (iii) a selected transgene operatively linked to regulatory sequences which direct its expression in a target cell, said transgene and regulatory sequences flanked by the AAV sequences of (ii).

Claim 37

A recombinant, replication-defective hybrid virus comprising: (a) adenovirus sequences comprising the adenovirus 5' and 3' cis-elements necessary for replication and virion encapsidation, said adenovirus sequences comprising a functional deletion in the E1, E2, E3, and E4 genes, (b) adeno-associated virus (AAV) sequences comprising the 5' and 3' inverted terminal repeats (ITRs) of an AAV, said AAV sequences flanked by the adenovirus sequences of (a); and (c) a selected transgene operatively linked to sequences which regulate its expression in a target cell, said transgene and regulatory sequences flanked by the AAV sequences of (b), wherein the hybrid virus is provided with sufficient adenovirus sequences to permit infection of a target cell and stable integration of the transgene into the target cell in the presence of a functional portion of an AAV rep gene.

Claim 38

A recombinant, replication-defective hybrid virus comprising: (a) adenovirus sequences comprising the adenovirus 5' and 3' cis-elements necessary for replication and virion encapsidation, said adenovirus sequences comprising a functional deletion in the E1, E2, E3, and E4 genes, (b) adeno-associated virus (AAV) sequences comprising the 5' and 3' inverted terminal repeats (ITRs) of an AAV, said AAV sequences flanked by the adenovirus sequences of (a); and (c) a selected transgene operatively linked to sequences which regulate its expression in a target cell, said transgene and regulatory sequences flanked by the AAV sequences of (b), wherein the hybrid virus is provided with sufficient adenovirus sequences to permit infection of a target cell and stable integration of the transgene into the target cell in the presence of a functional portion of an AAV rep gene.

Claim 39

The recombinant, replication-defective hybrid virus according to claim 31, wherein said adenovirus sequences further comprise a deletion in one or more of the adenovirus genes selected from the group consisting of late genes L1 through L5, and intermediate genes IX and IX a .

Claim 40

A recombinant trans-infection particle comprising: (a) the recombinant, replication-defective, hybrid virus according to claim 31; (b) a polycation sequence conjugated to said hybrid virus; and (c) a plasmid comprising a functional portion of an AAV rep gene operatively linked to sequences which regulate its expression, said plasmid bound to said polycation sequence.

Claim 41

A composition which delivers and stably integrates a selected transgene into the chromosome of a target cell, said composition comprising: (a) the recombinant trans-infection particle according to claim 33; and (b) a pharmaceutically acceptable carrier.

Claim 42

A hybrid adenovirus-adeno-associated virus vector encoded by SEQ ID NO: 1.

Claim 43

A hybrid adenovirus-adeno-associated virus vector encoded by SEQ ID NO: 1.